Literature DB >> 27452811

Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome.

Piotr Mazur, Tomasz Darocha, Grzegorz Filip, Grzegorz Grudzień, Rafał Drwiła, Bogusław Kapelak.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27452811     DOI: 10.20452/pamw.3470

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


× No keyword cloud information.
  6 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

2.  Assessment of patients post reversal with idarucizumab.

Authors:  Veronica Raco; Tania Ahuja; David Green
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

Review 3.  Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation.

Authors:  Jarosław Zalewski; Anetta Undas
Journal:  Postepy Kardiol Interwencyjnej       Date:  2016-11-17       Impact factor: 1.426

4.  Dabigatran level monitoring prior to idarucizumab administration in patients requiring emergent cardiac surgery.

Authors:  Radoslaw Litwinowicz; Janusz Konstanty-Kalandyk; Tadeusz Goralczyk; Krzysztof Bartus; Piotr Mazur
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

5.  Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.

Authors:  Milan R Vosko; Christof Bocksrucker; Rafał Drwiła; Petr Dulíček; Tomas Hauer; Johannes Mutzenbach; Christoph J Schlimp; David Špinler; Thomas Wolf; Daša Zugwitz
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300

6.  Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.

Authors:  Vítor Fagundes; Mari Mesquita
Journal:  Eur J Case Rep Intern Med       Date:  2019-12-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.